GLP-1 and GIP co-agonist compound

A technology of X1-X16, analogs, applied in animal/human proteins, hormone peptides, drug combinations, etc., can solve problems such as poor stability

Pending Publication Date: 2020-10-27
SHANGHAI HANSOH BIOMEDICAL +1
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] One of the shortcomings of polypeptide compounds as

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • GLP-1 and GIP co-agonist compound
  • GLP-1 and GIP co-agonist compound
  • GLP-1 and GIP co-agonist compound

Examples

Experimental program
Comparison scheme
Effect test
No Example Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a GLP-1 and GIP co-agonist compound. A series of human glucose-dependent insulinotropic polypeptide (GIP) based dual agonist compound and a pharmaceutical composition with available pharmaceutical salt is provided. The compound has dual agonist effects on human glucagon-like peptide-1 (GIP-1) receptors and human GIP receptors, and can be used for treating related diseases such as non-insulin dependent diabetes mellitus, insulin-dependent diabetes mellitus and obesity.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a dual agonist effect on human glucagon-like peptide-1 (GLP-1) receptors and human blood sugar-dependent insulinotropic polypeptide (GIP) receptors, which can be used for Compounds for the treatment of metabolic diseases such as non-insulin dependent diabetes mellitus, insulin dependent diabetes mellitus and obesity related diseases. Background technique [0002] Diabetes is a metabolic disease caused by the imbalance of glucose, protein and lipid metabolism in the human body caused by insufficient insulin secreted in the body. According to the difference of its pathological mechanism, diabetes is mainly divided into insulin-dependent diabetes (type I diabetes) and non-insulin-dependent diabetes (type II diabetes). Among them, 90-95% of diabetic patients worldwide are non-insulin-dependent diabetes. Non-insulin-dependent diabetes mellitus is a long-term, chronic metabolic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/575A61K38/22A61P3/10A61P3/04A61K45/06A61K31/155A61K31/426A61K31/64
CPCC07K14/575A61P3/10A61P3/04A61K45/06A61K31/155A61K31/426A61K31/64A61K38/00A61K2300/00
Inventor 吴方舟王雷刘潇吴然花海清包如迪王小雷
Owner SHANGHAI HANSOH BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap